Skip to content

A Study to Compare the Results of FGFR Testing by Either CtDNA Blood Testing or Standard Tumor Tissue Testing

Metastatic Urothelial Carcinoma | Metastatic Bladder Cancer

A new drug, erdafitinib, became available for some patients with bladder cancer that has spread to other organs. To qualify, patients must have specific genetic changes in their tumors. Currently, doctors use tumor tissue samples to check for these genetic changes, but these samples might not accurately reflect the current state of the patient's cancer.

In this study, Investigators will test the patient's blood for these genetic changes in addition to the tumor tissue samples. It is thought that the blood test will give a more accurate result.

Investigators hope this study will help to find out if more patients can benefit from erdafitinib than the ones identified by tissue testing only.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Patients with metastatic bladder cancer who are about to undergo tissue testing for FGFR mutations and who have blood samples drawn during the management of their disease are eligible to be included in this analysis.

Exclusion Criteria:

* Metastatic bladder cancer patients who will not have tissue sent for FGFR testing will be excluded from this study.

Study Location

Cross Cancer Institute
Cross Cancer Institute
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Project Manager

[email protected]
Backup Contact

Naveen Basappa

Princess Margaret Cancer Centre
Princess Margaret Cancer Centre
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Clinical Research Study Assistant

[email protected]
Backup Contact

Srikala Sridhar

Arthur J.E Child Comprehensive Cancer Centre
Arthur J.E Child Comprehensive Cancer Centre
Calgary, Alberta
Canada

Contact Study Team

Backup Contact

Nimira Alimohamed

Primary Contact

Clinical Research Coordinator

[email protected]
Ottawa Hospital Research Institute
Ottawa Hospital Research Institute
Ottawa, Ontario
Canada

Contact Study Team

Backup Contact

Michael Ong

Primary Contact

Research Coordinator

[email protected]
BC Cancer Agency
BC Cancer Agency
Vancouver, British Columbia
Canada

Contact Study Team

Backup Contact

Bernie Eigl

Primary Contact

Clinical Research and Trials Coordinator

[email protected]
CHU de Québec-Université Laval
CHU de Québec-Université Laval
Québec City, Quebec
Canada

Contact Study Team

Backup Contact

Paul Toren

Primary Contact

Research Coordinator

[email protected]
London Health Sciences Centre
London Health Sciences Centre
London, Ontario
Canada

Contact Study Team

Primary Contact

Research Coordinator

[email protected]
Backup Contact

Eric Winquist

Study Sponsored By
British Columbia Cancer Agency
Participants Required
More Information
Study ID: NCT06129084